| MeSH term | MeSH ID | Detail |
|---|---|---|
| beta-Thalassemia | D017086 | 5 associated lipids |
| Granulomatosis with Polyangiitis | D014890 | 5 associated lipids |
| Placenta Diseases | D010922 | 5 associated lipids |
| Thrombophilia | D019851 | 6 associated lipids |
| Periapical Periodontitis | D010485 | 6 associated lipids |
| Hyperlipoproteinemia Type IV | D006953 | 6 associated lipids |
| Glomerulonephritis, Membranous | D015433 | 6 associated lipids |
| Coronary Stenosis | D023921 | 6 associated lipids |
| Sneezing | D012912 | 6 associated lipids |
| Thromboembolism | D013923 | 6 associated lipids |
Thromboxane b2
Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
Cross Reference
Introduction
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Thromboxane b2?
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
PubChem Associated disorders and diseases
What pathways are associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Thromboxane b2?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Thromboxane b2?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Thromboxane b2?
There are no associated biomedical information in the current reference collection.
What genes are associated with Thromboxane b2?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Thromboxane b2?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with Thromboxane b2
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Montalescot G et al. | Early thromboxane release during pacing-induced myocardial ischemia with angiographically normal coronary arteries. | 1990 | Am. Heart J. | pmid:2248190 |
| Hirsh PD et al. | Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. | 1982 | Am. Heart J. | pmid:7102506 |
| Ikonomidis I et al. | Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. | 2005 | Am. Heart J. | pmid:15894964 |
| Tomoda H | Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). | 1986 | Am. Heart J. | pmid:3532743 |
| Buchanan MR et al. | Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease. | 1987 | Am. Heart J. | pmid:2953219 |
| Rubenstein MD et al. | Platelet activation in clinical coronary artery disease and spasm. | 1981 | Am. Heart J. | pmid:6455912 |
| De Caterina R et al. | Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects. | 1990 | Am. Heart J. | pmid:2321506 |
| Lorenzoni R et al. | Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. | 2004 | Am. Heart J. | pmid:15215815 |
| Mehta J et al. | Thromboxane release in coronary artery disease: spontaneous versus pacing-induced angina. | 1984 | Am. Heart J. | pmid:6695662 |
| De Servi S et al. | Coronary vasoconstrictor response to cold pressor test in variant angina: lack of relation to intracoronary thromboxane concentrations. | 1987 | Am. Heart J. | pmid:3630891 |
| O'Connor KM et al. | The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models. | 1989 | Am. Heart J. | pmid:2929400 |
| Zhu BQ and Parmley WW | Modification of experimental and clinical atherosclerosis by dietary fish oil. | 1990 | Am. Heart J. | pmid:2105047 |
| Neri Serneri GG et al. | Abnormal cardiocoronary thromboxane A2 production in patients with unstable angina. | 1985 | Am. Heart J. | pmid:3984828 |
| O'Connor KM et al. | Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. | 1986 | Am. Heart J. | pmid:3953390 |
| Roy L et al. | Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease. | 1985 | Am. Heart J. | pmid:3158183 |
| Austin JC et al. | Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion. | 1988 | Am. Heart J. | pmid:3344655 |
| Yamada Y et al. | Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator. | 1991 | Am. Heart J. | pmid:1903579 |
| FitzGerald GA et al. | Cigarette smoking and hemostatic function. | 1988 | Am. Heart J. | pmid:3276116 |
| Jouve R et al. | Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy. | 1984 | Am. Heart J. | pmid:6581715 |
| Rebuzzi AG et al. | Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. | 1992 | Am. Heart J. | pmid:1539506 |